Our study showed that differences exist in the distribution of transcriptional expression of ACRG in glioma, and this difference is independent of some classical glioma classification indicators, such as IDH, etc. Among them, AC-GII patients, who were characterized by high expression of HDAC4, EP300, and CREBBP, had the best prognosis and were sensitive to temozolomide and pan-HDACis. The gene discussed is CREBBP; the disease is glioma.